A House committee is requesting that NIH provide answers to 30 questions about the “pervasive culture of sexual harassment” in biomedical research.
NIH is now required by law to direct grantee institutions to report senior personnel who are disciplined for misconduct, sexual or otherwise.
Effective July 9, NIH-funded institutions that do not report relevant cases of misconduct—including sexual harassment, bullying, and retaliation—within one month would be considered to be in violation of NIH regulations and of federal law.
The House of Representatives on June 22 voted 336-85 to pass legislation that would establish the authorities of the Advanced Research Projects Agency-Health (ARPA-H), President Joe Biden’s proposed high-risk, high-reward biomedical research agency.
In a letter addressed to FDA Commissioner Robert Califf, Republican leaders of the House Committee on Energy and Commerce and two of its subcommittees raised questions about the increasing number of clinical trials conducted in China by companies seeking FDA approval for “me-too” checkpoint inhibitor drugs.
In testimony before the House Labor HHS Appropriations Subcommittee May 26, cancer organizations recommended FY23 appropriations of $49 billion for NIH, $7.76 billion for NCI, and $426.6 million for the CDC’s Division of Cancer Prevention and Control.
The same House appropriators who, with bipartisan resolve, oversaw years of dramatic funding increases for NIH expressed equally bipartisan misgivings about President Joe Biden’s proposal to boost funding for the Advanced Research Projects Agency for Health while giving NIH a meager raise—and cutting funds for NCI.
Before any strategy can be formulated for next year’s appropriations, cancer groups must confront the formidable challenge of figuring out how much of President Joe Biden’s vision for cancer research is realistic.
The FY22 spending bill increases NCI’s budget by $159 million—but according to NCI officials, this boost isn’t sufficient to raise paylines for R01 grants for established and new investigators.
Congress has extended FY22 spending talks once again, leaving the proposed Advanced Research Projects Agency for Health (ARPA-H)—a key piece of President Joe Biden’s cancer agenda—in limbo.
